These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 8589710)

  • 21. Dietary treatment of tyrosinosis.
    Hill A; Nordin PM; Zaleski WA
    J Am Diet Assoc; 1970 Apr; 56(4):308-12. PubMed ID: 5436184
    [No Abstract]   [Full Text] [Related]  

  • 22. Six novel mutations in the fumarylacetoacetate hydrolase gene of patients with hereditary tyrosinemia type I.
    Timmers C; Grompe M
    Hum Mutat; 1996; 7(4):367-9. PubMed ID: 8723690
    [No Abstract]   [Full Text] [Related]  

  • 23. Possibilities for treatment and for early prenatal diagnosis of hereditary tyrosinaemia.
    Holme E; Lindblad B; Lindstedt S
    Lancet; 1985 Mar; 1(8427):527. PubMed ID: 2857895
    [No Abstract]   [Full Text] [Related]  

  • 24. Two novel mutations involved in hereditary tyrosinemia type I.
    St-Louis M; Poudrier J; Phaneuf D; Leclerc B; Laframboise R; Tanguay RM
    Hum Mol Genet; 1995 Feb; 4(2):319-20. PubMed ID: 7757089
    [No Abstract]   [Full Text] [Related]  

  • 25. The sparse fur mouse as a model for gene therapy in ornithine carbamoyltransferase deficiency.
    Batshaw ML; Yudkoff M; McLaughlin BA; Gorry E; Anegawa NJ; Smith IA; Hyman SL; Robinson MB
    Gene Ther; 1995 Dec; 2(10):743-9. PubMed ID: 8750014
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A mouse model for human hereditary tyrosinemia I.
    Holdener BC; Magnuson T
    Bioessays; 1994 Feb; 16(2):85-7. PubMed ID: 8147847
    [No Abstract]   [Full Text] [Related]  

  • 27. Tyrosinemia: the Quebec experience.
    Paradis K
    Clin Invest Med; 1996 Oct; 19(5):311-6. PubMed ID: 8889268
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Spectrum of mutations in the fumarylacetoacetate hydrolase gene of tyrosinemia type 1 patients in northwestern Europe and Mediterranean countries.
    Bergman AJ; van den Berg IE; Brink W; Poll-The BT; Ploos van Amstel JK; Berger R
    Hum Mutat; 1998; 12(1):19-26. PubMed ID: 9633815
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Genetic aspects of tyrosinemia.
    Dallaire L
    Can Med Assoc J; 1967 Oct; 97(18):1098-9. PubMed ID: 6050913
    [No Abstract]   [Full Text] [Related]  

  • 30. Hawkinsinuria: a dominantly inherited defect of tyrosine metabolism with severe effects in infancy.
    Wilcken B; Hammond JW; Howard N; Bohane T; Hocart C; Halpern B
    N Engl J Med; 1981 Oct; 305(15):865-8. PubMed ID: 7278885
    [No Abstract]   [Full Text] [Related]  

  • 31. Outcome of therapy of hereditary tyrosinemia.
    Halvorsen S; Kvittingen EA; Flatmark A
    Acta Paediatr Jpn; 1988 Aug; 30(4):425-8. PubMed ID: 3150231
    [No Abstract]   [Full Text] [Related]  

  • 32. The enzymatic deficiency in tyrosinemia.
    Du BN
    Can Med Assoc J; 1967 Oct; 97(18):1076-8. PubMed ID: 6050909
    [No Abstract]   [Full Text] [Related]  

  • 33. The phenotypic manifestations of hereditary tyrosinemia and tyrosyluria: a hypothesis.
    Scriver CR
    Can Med Assoc J; 1967 Oct; 97(18):1073-5. PubMed ID: 6050908
    [No Abstract]   [Full Text] [Related]  

  • 34. [Molecular pathology and DNA diagnosis of phenylketonuria and hypermethioninemia].
    Nagao M
    Tanpakushitsu Kakusan Koso; 1998 May; 43(6):762-9. PubMed ID: 9612070
    [No Abstract]   [Full Text] [Related]  

  • 35. [Other abnormalities of tyrosine metabolism].
    Endo F
    Ryoikibetsu Shokogun Shirizu; 1998; (18 Pt 1):144-5. PubMed ID: 9590010
    [No Abstract]   [Full Text] [Related]  

  • 36. Characteristics of murine histidinaemia and its potential for genetic manipulation.
    Mellor N; Themis M; Selden C; Jones M; Hodgson HJ
    Liver Int; 2004 Aug; 24(4):354-60. PubMed ID: 15287859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perspectives of liver cell transplantation: a review.
    Schmidt HH; Tietge UJ; Manns MP
    Hepatogastroenterology; 1997; 44(16):1013-8. PubMed ID: 9261591
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tyrosinaemia type I: considerations of treatment strategy and experiences with risk assessment, diet and transplantation.
    van Spronsen FJ; Smit GP; Wijburg FA; Thomasse Y; Visser G; Heymans HS
    J Inherit Metab Dis; 1995; 18(2):111-4. PubMed ID: 7564222
    [No Abstract]   [Full Text] [Related]  

  • 39. Observations on treatment in patients with tyrosyluria.
    Sass-Kortsak A; Ficici S; Paunier L; Kooh SW; Fraser D; Jackson SH
    Can Med Assoc J; 1967 Oct; 97(18):1089-95. PubMed ID: 6050911
    [No Abstract]   [Full Text] [Related]  

  • 40. Pathological findings in patients with tyrosinemia.
    Prive L
    Can Med Assoc J; 1967 Oct; 97(18):1054-6. PubMed ID: 6050905
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.